Stemtech

Stemtech EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Stemtech (STEK) as of Nov 3, 2026 is 0.02. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 0.01 — a change of 75.70% (higher).

EV/Revenue

0.02

YoY

75.70%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Stemtech is 2025 0.02 . EV/Revenue (Enterprise Value to Revenue) of Stemtech was 2024 0.01 . It decreases by 75.70% higher compared to the previous year.

The Stemtech EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2019
0.03 USD
Jan 1, 2020
0.19 USD
Jan 1, 2021
0.16 USD
Jan 1, 2022
0.22 USD
Jan 1, 2023
0.01 USD
Jan 1, 2024
0.01 USD
Jan 1, 2025
0.02 USD
The Stemtech EV/Revenue history
YEAREV/RevenueYoY
0.02+75.70%
0.01-2.62%
0.01-93.61%
0.22+38.19%
0.16-14.96%
0.19+515.29%
0.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stemtech Stock analysis

What does Stemtech do? Stemtech Corp develops nutritional supplements that support stem cell activity, marketed internationally through subsidiaries and independent distributors. The company's products include the RCM System, stemrelease3, Stemflo MigraStem, OraStem for oral health, and D-Fuze for electromagnetic frequency blocking. Cellect One Rapid Renew Stem Cell Peptide Night Cream is its skincare offering. Products are sold in North America, Latin America, and Asia through distributors and subsidiaries. The firm's brands target health-conscious consumers seeking stem cell support, with OraStem focusing on oral care and D-Fuze addressing electromagnetic frequency concerns. Independent distributors handle sales across all segments, leveraging the company's international presence. The RCM System and stemrelease3 are core products for general stem cell enhancement. Stemtech Corp's revenue streams come from direct sales of its branded nutritional supplements and skincare products. Distributors purchase products from subsidiaries to resell, generating consistent income through these channels. The company's international segments ensure diverse market coverage without relying on a single region. Stemtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stemtech stock

EV/Revenue (Enterprise Value to Revenue) of Stemtech is 0.02 in 2025.

EV/Revenue (Enterprise Value to Revenue) of Stemtech changed from 0.01 to 0.02, representing a 75.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Stemtech since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Stemtech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Stemtech

All Key Metrics — Stemtech